![]() ![]() This cookie is native to PHP applications. The cookie is used to remember the user consent for the cookies under the category "Performance". This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to store the user consent for the cookies in the category "Necessary". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting". These cookies do not store any personal information.Ĭookielawinfo-checkbox-advertising-targeting This category only includes cookies that ensures basic functionalities and security features of the website. Necessary cookies are absolutely essential for the website to function properly. The cell and gene therapy CDMO bottleneck isn’t capacity – it’s capability The new facility is expected to be fully operational by 2025. The project is expected to be completed in December 2024. This opportunity will add to the team, which currently has approximately 200 employees. The investment is expected to create 100 jobs in the region. When the new site is up and running, our existing capacity will be transformed to new microbial protein suites.” Ultimately, the addition will enable the CDMO to undertake larger-scale viral vector as well as microbial protein projects and concurrent manufacturing campaigns, by increasing overall production capacity and flexibility.Īccording to the contract development and manufacturing organisation’s CEO, the expanded facility “will increase viral vector capacity, but it will also increase our capacity and flexibility in microbial protein. The evolution of AAVs in cell and gene therapyīiovian’s new space adds to the company’s existing manufacturing facilities in the area. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |